Boston Scientific discontinues ACURATE aortic valve systems globally; maintains adjusted EPS guidance

BOSTON SCIENTIFIC CORP

Discontinuing worldwide sales of ACURATE neo2 and ACURATE Prime Aortic Valve Systems; no longer pursuing U.S. FDA or other approvals.
Decision driven by increased regulatory requirements and prohibitive additional investments needed to maintain or obtain approvals.
Still expects to achieve Q2 and full year 2025 reported and organic sales and adjusted EPS guidance issued on April 23.
Not reaffirming Q2 and full year 2025 GAAP EPS guidance at this time; more details on Q2 2025 earnings call.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.